DiaSorin (OTCMKTS:DSRLF – Get Free Report) is expected to be announcing its resultson Friday, July 31st. Analysts expect DiaSorin to announce earnings of $1.12 per share and revenue of $357.7870 million for the quarter.
DiaSorin Trading Up 1.3%
DiaSorin stock opened at $81.00 on Thursday. The company has a 50 day moving average of $78.09 and a 200-day moving average of $76.58. DiaSorin has a twelve month low of $66.50 and a twelve month high of $100.00.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on DSRLF shares. UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Zacks Research raised DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Piper Sandler initiated coverage on DiaSorin in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft cut DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, June 17th. Finally, BNP Paribas Exane lowered DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, DiaSorin presently has a consensus rating of “Hold”.
About DiaSorin
DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.
At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.
Read More
- Five stocks we like better than DiaSorin
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.
